Also worth noting PMS has the largest estimated patient population out of the 4 trials, then Angelman, then PW, then a fair drop to PH. To me, PMS is the most significant positive result to have. All are important, however there are relative populations to consider as well. Absolutely agree that multiple positive trials only enhances the general effectiveness argument for 2591. However, PMS alone is a very big deal.
Share Price, page-10098
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.70 |
Change
0.395(2.05%) |
Mkt cap ! $2.516B | |||
| Open | High | Low | Value | Volume |
| $19.80 | $20.00 | $19.40 | $2.060M | 104.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 251 | $19.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.70 | 15 | 4 |
View Market Depth
| Last trade - 14.29pm 11/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |